

PSYCHOACTIVE COMPOUND ASSOCIATED MARKERS AND METHOD OF USE THEREOF

RELATED APPLICATIONS

5 This application claims priority to U.S.S.N. 60/457,753 filed March 26, 2003, which is hereby incorporated by reference herein in its entirety

FIELD OF THE INVENTION

The invention relates generally to the identification of genetic markers associated with psychoactive compounds.

BACKGROUND OF THE INVENTION

10 Microarray-based gene expression patterns can be used as fingerprints of cellular physiology. The variety of cellular physiologies discernable by gene expression profile fingerprinting is expanding as an increasing range of cell types and cellular manipulations are investigated, and statistical methods of expression profile classification are refined. In yeast, distinctive profiles of genomic expression have been used to characterize cellular responses to diverse environmental transitions, functionally classify genetic manipulations and discover a novel target for a drug of partially characterized function. In cancer studies, microarray data has been used to classify solid tumors, correlate tumor characteristics to clinical outcome, and cluster cell lines on the basis of their tissue of origin and response to drugs. In the area of toxicogenomics, large-scale analysis of toxin-treated cells and animals has resulted in a highly accurate capacity to recognize toxic profiles induced by novel drug candidates on the basis of gene expression, resulting in an increase in the efficiency of drug triage in the pharmaceutical development pipeline.

SUMMARY OF THE INVENTION

25 The invention is based in part on the discovery that certain nucleic acids are differentially expressed neuronal cells treated with psychoactive compounds. Psychoactive compounds include for example, an antidepressant compound, an antipsychotic compound or an opioid receptor agonist

These differentially expressed nucleic acids while previously described, have not heretofore been identified as associated with psychoactive activity and are collectively referred to herein as "PSYCHMARKER nucleic acids" or "PSYCHMARKER polynucleotides" and the corresponding encoded polypeptides are referred to as "PSYCHMARKER polypeptides" or "PSYCHMARKER proteins". The PSYCHMARKER genes are useful in high throughput screening of potential therapeutic compounds for psychoactive activity. By psychoactive activity is meant that the compound alleviates a sign or symptom of a psychiatric disorder of depression, schizophrenia or pain.

In one aspect the invention provides methods of identifying a psychoactive compound or identifying drug efficacy of a psychoactive compound. By drug efficacy is meant that the compound confers a clinical benefit such as alleviating a symptom of a psychiatric disorder of depression, schizophrenia or pain. Psychoactive compounds are identified or drug efficacy is determined by determining the level of expression of a psychoactive-associated gene in a cell exposed to a test agent. The level of expression of the psychoactive -associated gene is compared to the level of expression of the psychoactive -associated gene in a control population exposed to a control agent. A test agent is predicted to have psychoactive activity if an alteration (e.g., increase or decrease) in the level of expression in the cell exposed to the test agent compared to the control population is identified. The method further provides for the identification of a functional category (e.g., antidepressant, antipsychotic compound or opioid receptor agonist) of a psychoactive drug to be determined.

Also provided by the invention are methods of screening a test agent for inducing changes in gene expression associated with a psychoactive compound. An agent is screened for inducing changes in gene expression associated with a psychoactive compound by determining the level of expression of a psychoactive -associated gene in a cell exposed to a test agent. The level of expression of the psychoactive -associated gene is compared to the level of expression of the psychoactive -associated gene in a control population exposed to a control agent.

The alteration is statistically significant. By statistically significant is meant that the alteration is greater than what might be expected to happen by chance alone. Statistical significance is determined by method known in the art. An alteration is statistically significant if the p-value is at least 0.05. Preferably, the p-value is 0.04, 0.03, 0.02, 0.01, 0.005, 0.001 or less.

By psychoactive - associated gene is meant a gene that is characterized by a level of expression which differs in a cell exposed to a psychoactive compound compared to a control population. A psychoactive -associated gene includes for example PSYCHMARKER 1-13.

A control population is a for example a cell not exposed to a psychoactive compound.

5 Optionally, the control population is exposed to a control agent. A control agent is an agent that does not elicit psychoactive activity. A control level is a single expression pattern derived from a single control population or from a plurality of expression patterns. For example, the control level can be a database of expression patterns from previously tested cells.

10 The test cell is provided *in vitro*. Alternatively, the test cell is provided *ex vivo* or *in vivo* from a mammalian subject. The test cell is derived from neuronal tissue. Expression is determined by for example detecting hybridization, *e.g.*, on a chip, of a toxicity-associated gene probe to a gene transcript of the test cell.

The invention also provides a psychoactive compound reference expression profile of a gene expression level two or more of PSYCHMARKER 1-13. For example, the reference profile
15 contains the expression levels of PSYCHMARKER 1-13.

The invention also provides a kit with a detection reagent which binds to two or more PSYCHMARKER nucleic acid sequences or which binds to a gene product encoded by the nucleic acid sequences. Also provided is an array of nucleic acids, *e.g.* oligonucleotides that binds to two or more PSYCHMARKER nucleic acids. For example, the array contains oligonucleotides that bind
20 PSYCHMARKER 1-13.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All
25 publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed
30 description and claims.

DETAILED DESCRIPTION

The present invention is based in part on the discovery of changes in expression patterns of multiple nucleic acid sequences in response to compounds known to elicit psychoactive activity, e.g., antidepressant activity, antipsychotic activity or opioid receptor agonist activity. The differences in gene expression were identified by treating human primary neurons with multiple members of multiple classes of antidepressant drugs, antipsychotic drugs and opioid receptor agonists, followed by DNA microarray analysis of gene expression, to derive example gene expression profiles from these drug treatments. These expression profiles were used to construct statistical models capable of predicting drug efficacy based on a gene expression pattern. The set of biomarker genes that were derived, when considered together, predict the functional category of members of each of these drug classes (e.g., antidepressant, antipsychotic, or opioid receptor agonist) with at least 83.3 % (Random Forest) or 88.9 % (Classification Tree) accuracy, based on analysis of their expression levels induced by a drug. The ability to identify drug efficacy or activity on the basis of expression of the mRNA of these genes induced *in vitro* is useful in validation of drug targets for the treatment of the psychiatric disorders of depression, schizophrenia and pain.

The genes whose expression levels are modulated (*i.e.*, increased or decreased) response to a psychoactive compound are summarized in Tables 1 and are collectively referred to herein as "psychoactive compound-associated genes", "PSYCHMARKER nucleic acids" or "PSYCHMARKER polynucleotides" and the corresponding encoded polypeptides are referred to as "PSYCHMARKER polypeptides" or "PSYCHMARKER proteins." Unless indicated otherwise, "PSYCHMARKER" is meant to refer to any of the sequences disclosed herein. (e.g., PSYCHMARKER 1-13). By measuring the expression of these genes in response to various agents, agents for treating psychiatric disorders of depression, schizophrenia and pain are identified.

Table 1 Psychoactive Compound-Associated Genes

Gene	PSYCHMARKER
PTX3 pentaxin 3	1
ILK integrin linked kinase	2
ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6	3
GPCR CG50207	4
SFRS7 splicing factor, arginine/serine-rich 7	5
CBRC7TM 424 GPCR	6
APAF-1 apoptotic protease activating factor 1	7
ERMAP erythroblast membrane-associated protein	8

CGFLC 31120	9
LYPLA1 lysophospholipase I	10
LDHA Lactate dehydrogenase A	11
SCG3	12
CG187232	13

The invention involves determining (*e.g.*, measuring) the expression of at least one, and up to all the PSYCHMARKER genes listed in Table 1. Using sequence information provided the psychoactive compound-associated genes are detected and measured using techniques well known to one of ordinary skill in the art. For example, sequences within the sequence database entries corresponding to PSYCHMARKER sequences, are used to construct probes for detecting PSYCHMARKER RNA sequences in, *e.g.*, northern blot hybridization analyses. As another example, the sequences can be used to construct primers for specifically amplifying the PSYCHMARKER sequences in, *e.g.*, amplification-based detection methods such as reverse-transcription based polymerase chain reaction.

Expression level of one or more of the PSYCHMARKER sequences in the test cell population, *e.g.*, a neuronal cell, is then compared to expression levels of the some sequences in a reference population. The reference cell population includes one or more cells for which the compared parameter is known. The compared parameter can be, *e.g.*, psychoactive compound expression status. By “psychoactive compound expression status” is meant that it is known whether the reference cell has had contact with a psychoactive compound. If desired, a reference expression profile is generated. A reference profile is a single expression pattern derived from a single reference population or from a plurality of expression patterns. For example, the reference cell population can be a database of expression patterns from previously tested cells for which one of the herein-described parameters or conditions is known.

Whether or not comparison of the gene expression profile in the test cell population to the reference cell population reveals the presence, or degree, of the measured parameter depends on the composition of the reference cell population. For example, if the reference cell population is composed of cells not exposed to a known psychoactive compound, a similar gene expression level in the test cell population and reference cell population indicates the test compound is not a psychoactive compound. Conversely, if the reference cell population is made up of cells exposed to

a psychoactive compound, a similar gene expression profile between the test cell population and the reference cell population indicates that the test compound is a psychoactive compound.

Expression of sequences in test and reference populations of cells are compared using any art recognized method for comparing expression of nucleic acid sequences. For example, expression can be compared using a gene microarray such as CuraChipTM. CuraChip provides a high-throughput means of global mRNA expression analyses of cDNA sequences representing the Pharmaceutically Tractable Genome (PTG). The CuraChipTM cDNAs are represented as 30-mer oligodeoxyribonucleotides (oligos) on a glass microchip. Hybridization methods using the longer CuraChipTM oligos are more specific compared with methods using 25-mer oligos. CuraChipTM oligos are synthesized with a linker, purified to remove truncated oligos (which can influence hybridization strength and specificity), and spotted on a glass slide. Details of the method used are described in Example 1. Alternatively, expression can be compared using GENECalling[®] methods as described in US Patent No. 5,871,697 and in Shimkets et al., Nat. Biotechnol. 17:798-803.

An PSYCHMARKER sequence in a test cell population can be considered altered in levels of expression if its expression level varies from the reference cell population by more than 1.0, 1.5, 2.0, 5.0, 10.0 or more fold from the expression level of the corresponding PSYCHMARKER sequence in the reference cell population

If desired, comparison of differentially expressed sequences between a test cell population and a reference cell population can be done with respect to a control nucleic acid whose expression is independent of the parameter or condition being measured. For example, a control nucleic acid is one which is known not to differ depending on the exposure of the cell to a psychoactive compound. Expression levels of the control nucleic acid in the test and reference nucleic acid can be used to normalize signal levels in the compared populations. Control genes can be, *e.g.*, β -actin, glyceraldehyde 3- phosphate dehydrogenase or ribosomal protein P1 (36B4).

The test cell population is compared to multiple reference cell populations. Each of the multiple reference populations may differ in the known parameter. Thus, a test cell population may be compared to a first reference cell population known to contain, *e.g.*, cells exposed to an antidepressant compound, as well as a second reference population known to contain, *e.g.*, an antipsychotic compound.

The test cell population can be divided into two or more subpopulations. The subpopulations can be created by dividing the first population of cells to create as identical a subpopulation as possible. This will be suitable, in, for example, *in vitro* or *ex vivo* screening methods. In some embodiments, various subpopulations can be exposed to a control agent, and/or a test agent, multiple test agents, or, *e.g.*, varying dosages of one or multiple test agents administered together, or in various combinations.

The test cell population comprises a neuronal cell. Preferably, the test cell population is a human neuronal cell. Cells in the reference cell population are derived from a tissue type as similar to test cell. Alternatively, the control cell population is derived from a database of molecular information derived from cells for which the assayed parameter or condition is known.

The subject is preferably a mammal. The mammal can be, *e.g.*, a human, non-human primate, mouse, rat, dog, cat, horse, or cow.

The expression of 1, 2, 3, 4, 5, 10 or more of the sequences represented by PSYCHMARKER 1-13 is determined and if desired, expression of these sequences can be determined along with other sequences whose level of expression is known to be altered according to one of the herein described parameters or conditions.

Expression of the genes disclosed herein is determined at the RNA level using any method known in the art. For example, Northern hybridization analysis using probes which specifically recognize one or more of these sequences can be used to determine gene expression. Alternatively, expression is measured using reverse-transcription-based PCR assays, *e.g.*, using primers specific for the differentially expressed sequences.

Expression is also determined at the protein level, *i.e.*, by measuring the levels of polypeptides encoded by the gene products described herein. Such methods are well known in the art and include, *e.g.*, immunoassays based on antibodies to proteins encoded by the genes.

When alterations in gene expression are associated with gene amplification or deletion, sequence comparisons in test and reference populations can be made by comparing relative amounts of the examined DNA sequences in the test and reference cell populations.

PREDICTION OF PSYCHOACTIVE ACTIVITY

In one aspect, the invention provides a method of predicting or identifying agents with psychoactive activity. By “psychoactive activity” is meant that the compound has antidepressant activity, antipsychotic activity or opioid receptor agonist activity. Psychoactive activity is measured by methods known to those skilled in the art. Antidepressant activity defined by the inhibition of monoamine oxidase, inhibition of serotonin reuptake, inhibition of norepinephrine reuptake, inhibition of dopamine reuptake or an increase in serotonergic neurotransmission. Antipsychotic activity is defined by dopamine, serotonin or glutamate receptor blockade or an alleviation of a symptom of a psychotic disorder such as schizophrenia, bipolar disorder or mania. Opioid receptor agonist activity is defined as the inhibition of an opioid receptor or the alleviation of pain.

The method is an *in vivo* method. Alternatively, the method is an *in vitro* method.

By predicting the psychoactive activity is meant that the test compound is more likely to be a psychoactive compound, *i.e.*, an antidepressant, an antipsychotic or an opioid receptor agonist than not be psychoactive. Psychoactive activity is predicted by determining the level of expression of a psychoactive-associated gene in a cell exposed to a test agent. The level of expression of the psychoactive-associated gene is compared to the level of expression of the psychoactive-associated gene in a control population exposed to a control agent. A test agent is predicted to be psychoactive if an alteration (*e.g.*, increase or decrease) in the level of expression in the cell exposed to the test agent compared to the control population is identified.

The toxicity-associated gene is for example PSYCHMARKER 1-13. The toxicity-associated gene is a nucleic acid sequence homologous to those listed in Table 1 as PSYCHMARKER 1-13. The sequences need not be identical to sequences including PSYCHMARKER 1-13, as long as the sequence is sufficiently similar that specific hybridization can be detected.

The cell population is contacted *in vitro*, or *in vivo*. Optionally, the cell population is contacted *ex vivo* with the agent or activated form of the agent.

Expression of the nucleic acid sequences in the test cell population is then compared to the expression of the nucleic acid sequences in a control population, which is a cell population that has not been exposed to the test agent, or, in some embodiments, a cell population exposed to the test agent. Comparison can be performed on test and reference samples measured concurrently or at temporally distinct times. An example of the latter is the use of compiled expression information, *e.g.*, a sequence database, which assembles information about expression levels of known sequences

following administration of various agents. For example, alteration of expression levels following administration of test agent can be compared to the expression changes observed in the nucleic acid sequences following administration of a control agent. Preferably, the alteration in expression levels are within the alteration range listed on Table 5. A control agent is a compound that is known to be psychoactive compound. Alternatively, the control agent is a compound that is not a psychoactive compound. Exemplary control compounds are listed in the Examples.

An alteration in expression of the nucleic acid sequence in the test cell population compared to the expression of the nucleic acid sequence in the control cell population that has not been exposed to the test agent indicates the test agent is a psychoactive compound.

The alteration is statistically significant. By statistically significant is meant that the alteration is greater than what might be expected to happen by chance alone. Statistical significance is determined by method known in the art. Multiple statistical methods have been applied to classification and recognition of expression profiles. For example, supervised classification analysis methods that classify patterns of data based on prior knowledge of sample classes include linear discriminant analysis and genetic algorithm/K-nearest neighbors (See Toxicol. Sci. 2002, 67:232-240, FEBS Lett. 2002, 522: 24-28), Fisher discriminant analysis (See Bioinformatics, 2002, 18:1054-1063), support vector machines (See Proc. Natl. Acad. Sci. USA, 2002, 262-267), neural networks (See Cancer Res. 2002, 62:3493-3497) and tree-based analysis (Front. Biosci. 2002, 7:c62-c67). An alteration is statistically significant if the prediction is at least 80% accurate. Preferably, the prediction is at least 82%, 83%, 85%, 88%, 90%, 92%, 95%, 99% or more accurate. Alternatively, statistical significance is determined by p-value. The p-value is a measure of probability that a difference between groups during an experiment happened by chance. ($P(z \geq z_{\text{observed}})$). For example, a p-value of 0.01 means that there is a 1 in 100 chance the result occurred by chance. The lower the p-value, the more likely it is that the difference between groups was caused by treatment. An alteration is statistically significant if the p-value is at least 0.05. Preferably, the p-value is 0.04, 0.03, 0.02, 0.01, 0.005, 0.001 or less.

The invention also includes a psychoactive compound identified according to this screening method. The differentially expressed PSYCHMARKER sequences identified herein also allow for the efficacy of a psychoactive compound to be determined or monitored. In this method, a test cell population from a subject is exposed to a test agent, *i.e.* a psychoactive compound. If desired, test cell populations can be taken from the subject at various time points before, during, or after

exposure to the test agent. Expression of one or more of the PSYCHMARKER sequences, *e.g.*, PSYCHMARKER: 1-13, in the cell population is then measured and compared to a control population which includes cells whose psychoactive compound expression status is known.

5 IDENTIFYING AGENTS THAT INHIBIT OR ENHANCE A PSYCHOACTIVE-ASSOCIATED GENE

An agent that inhibits the expression or activity of psychoactive -associated gene is identified by contacting a test cell population expressing metastatic lesions of colorectal cancer associated upregulated gene with a test agent and determining the expression level of the psychoactive - associated gene.

10 The test cell population is any cell expressing the psychoactive -associated genes. For example, the test cell population contains a neuronal cell or is derived from a neuronal tissue. For example, the test cell is immortalized cell line derived from a neuronal tissue.

15 SELECTING A THERAPEUTIC AGENT FOR TREATING PSYCHIATRIC DISORDERS OF DEPRESSION, SCHIZOPHRENIA AND PAIN THAT IS APPROPRIATE FOR A PARTICULAR INDIVIDUAL

Differences in the genetic makeup of individuals can result in differences in their relative abilities to metabolize various drugs. An agent that is metabolized in a subject to act as an psychoactive compound can manifest itself by inducing a change in gene expression pattern in the subject's cells. Accordingly, the differentially expressed PSYCHMARKER sequences disclosed
20 herein allow for a putative therapeutic or prophylactic psychoactive compound to be tested in a test cell population from a selected subject in order to determine if the agent is a suitable psychoactive compound in the subject.

To identify a psychoactive compound, that is appropriate for a specific subject, a test cell population from the subject is exposed to a therapeutic agent, and the expression of one or more of
25 PSYCHMARKER 1-13 sequences is determined.

The test cell population contains neuronal cells expressing psychoactive-associated gene. For example a test cell population is incubated in the presence of a candidate agent and the pattern of gene expression of the test sample is measured and compared to one or more reference profiles. An alteration in expression of one or more of the sequences PSYCHMARKER 1-13 in a test cell
30 population relative to a reference cell population is indicative that the agent is therapeutic. An agent

is therapeutic if it confers a clinical benefit such as alleviating a sign or symptom of a depression disorder, a psychotic disorder or a pain-related disorder.

Symptoms of depression include for example, persistently sad, anxious, or "empty" mood, feelings of hopelessness, pessimism, feelings of guilt, worthlessness, helplessness, loss of interest or pleasure in hobbies and activities that were once enjoyed, including sex, insomnia, early-morning awakening, or oversleeping, decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, thoughts of death or suicide, suicide attempts, restlessness and irritability. Depression is diagnosed for example by a physician performing a complete history of the patient's symptoms including (1) when did the symptoms start (2) how long have they lasted (3) how severe are they and (4) have the symptoms occurred before, and, if so, were they treated and what treatment was received.

Psychotic disorders include schizophrenia, schizoaffective disorder, brief psychotic disorder or mania. Symptoms of psychotic disorders include for example, delusions, hallucinations, disorganized speech (e.g., frequent derailment or incoherence) or grossly disorganized or catatonic behavior. Psychotic disorders are diagnosed by a doctor performing a complete medical history and physical examination to determine the cause of the symptoms. No laboratory tests to specifically diagnose psychotic disorders -- except those that accompany a physical illness, such as a brain tumor -- the doctor may use various tests, such as blood tests and X-rays, to rule out physical illness as the cause of the symptoms.

KITS

The invention also includes a PSYCHMARKER-detection reagent, e.g., a nucleic acid that specifically binds to or identifies one or more PSYCHMARKER nucleic acids such as oligonucleotide sequences, which are complementary to a portion of a PSYCHMARKER nucleic acid or antibodies which bind to proteins encoded by a PSYCHMARKER nucleic acid. For example the oligonucleotides are 200, 150, 100, 50, 25, 10 or less nucleotides in length. The reagents are packaged together in the form of a kit. The reagents are packaged in separate containers, e.g., a nucleic acid or antibody (either bound to a solid matrix or packaged separately with reagents for binding them to the matrix), a control reagent (positive and/or negative), and/or a detectable label. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay are included in the kit. The assay format of the kit is a Northern hybridization or a sandwich ELISA known in the art.

For example, PSYCHMARKER detection reagent, is immobilized on a solid matrix such as a porous strip to form at least one PSYCHMARKER detection site. The measurement or detection region of the porous strip may include a plurality of sites containing a nucleic acid. A test strip may also contain sites for negative and/or positive controls. Alternatively, control sites are located on a separate strip from the test strip. Optionally, the different detection sites may contain different amounts of immobilized nucleic acids, *i.e.*, a higher amount in the first detection site and lesser amounts in subsequent sites. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication of the amount of PSYCHMARKER present in the sample. The detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a teststrip.

Alternatively, the kit contains a nucleic acid substrate array comprising one or more nucleic acid sequences. The nucleic acids on the array specifically identify one or more nucleic acid sequences represented by PSYCHMARKER 1-13. The expression of 2, 3, 4, 5, 6, 7, 8, 9, 10, or more of the sequences represented by PSYCHMARKER 1-13 are identified by virtue of the level of binding to an array test strip or chip. The substrate array can be on, *e.g.*, a solid substrate, *e.g.*, a “chip” as described in U.S. Patent No. 5,744,305.

ARRAYS AND PLURALITIES

The invention also includes a nucleic acid substrate array comprising one or more nucleic acid sequences. The nucleic acids on the array specifically corresponds to one or more nucleic acid sequences represented by PSYCHMARKER 1-13. The level expression of 2, 3, 4, 5, 6, 7, 8, 9, 10, or more of the sequences represented by PSYCHMARKER 1-13 are identified by detecting nucleic acid binding to the array.

The invention also includes an isolated plurality (*i.e.*, a mixture of two or more nucleic acids) of nucleic acid sequences. The nucleic acid sequences are in a liquid phase or a solid phase, *e.g.*, immobilized on a solid support such as a nitrocellulose membrane. The plurality includes one or more of the nucleic acid sequences represented by PSYCHMARKER 1-13. In various embodiments, the plurality includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more of the sequences represented by PSYCHMARKER 1-13.

CHIPS

The DNA chip is a device that is convenient to compare expression levels of a number of

genes at the same time. DNA chip-based expression profiling can be carried out, for example, by the method as disclosed in "Microarray Biochip Technology " (Mark Schena, Eaton Publishing, 2000), etc.

A DNA chip comprises immobilized high-density probes to detect a number of genes. Thus, expression levels of many genes can be estimated at the same time by a single-round analysis. Namely, the expression profile of a specimen can be determined with a DNA chip. The DNA chip-based method of the present invention comprises the following steps of:

(1) synthesizing cRNAs or cDNAs corresponding to the marker genes;

(2) hybridizing the cRNAs or cDNAs with probes for marker genes; and

(3) detecting the cRNA or cDNA hybridizing with the probes and quantifying the amount of mRNA thereof.

The cRNA refers to RNA transcribed from a template cDNA with RNA polymerase. A cRNA transcription kit for DNA chip-based expression profiling is commercially available. With such a kit, cRNA can be synthesized from T7 promoter-attached cDNA as a template by using T7 RNA polymerase. On the other hand, by PCR using random primer, cDNA can be amplified using as a template a cDNA synthesized from mRNA.

On the other hand, the DNA chip comprises probes, which have been spotted thereon, to detect the marker genes of the present invention. There is no limitation on the number of marker genes spotted on the DNA chip. For example, it is allowed to select 5% or more, preferably 20% or more, more preferably 50% or more, still more preferably 70 % or more of the marker genes of the present invention. Any other genes as well as the marker genes can be spotted on the DNA chip. For example, a probe for a gene whose expression level is hardly altered may be spotted on the DNA chip. Such a gene can be used to normalize assay results when assay results are intended to be compared between multiple chips or between different assays.

A probe is designed for each marker gene selected, and spotted on a DNA chip. Such a probe may be, for example, an oligonucleotide comprising 5-50 nucleotide residues. A method for synthesizing such oligonucleotides on a DNA chip is known to those skilled in the art. Longer DNAs can be synthesized by PCR or chemically. A method for spotting long DNA, which is synthesized by PCR or the like, onto a glass slide is also known to those skilled in the art. The prepared DNA chip is contacted with cRNA, followed by the detection of hybridization between the probe and cRNA. The cRNA can be previously labeled with a fluorescent dye. A fluorescent dye such as Cy3(red) and Cy5 (blue) can be used to label a cRNA. cRNAs from a subject and a control are labeled with different fluorescent dyes, respectively. The difference in the expression level

between the two can be estimated based on a difference in the signal intensity. The signal of fluorescent dye on the DNA chip can be detected by a scanner and analyzed by using a special program. For example, the Suite from Affymetrix is a software package for DNA chip analysis.

Also the expression level of the marker gene(s) can be analyzed based on activity or quantity of protein(s) encoded by the marker gene(s). A method for determining the quantity of the protein(s) is known to those skilled in the art. For example, immunoassay method is useful for determination of the protein in biological material. Any biological materials can be used for the determination of the protein or its activity. Alternatively, a suitable method is selected for the determination of the activity protein(s) encoded by the marker gene(s) according to the activity of each protein to be analyzed.

EXAMPLE 1: GENERAL METHODS

To generate expression profiles of different drug class treatments, antidepressants, antipsychotics and opioid receptor agonists were administered to primary human neuronal cultures. The assays were carried out as follows.

Cell culture

Primary human neuronal precursor cells (Clonexpress, Gaithersburg, MD) derived from 14-16 week embryos were cultured seven days in growth media (50:50 DMEM/F12, 5% FBS, 10ng/ml bFGF, 10 ng/ml EGF, 1:100 Clonexpress neuronal cell supplement (NCS), pen/strep). To differentiate into neuronal phenotype, cells were plated in poly-L-lysine coated 6-well plates at 900,000 cells/well and cultured seven days in differentiation media (50:50 DMEM/F12 + 5% FBS, 10ng/ml bFGF, 10 ng/ml EGF, 1:100 NCS, pen/strep, 100μM dibutyryl CAMP, 20 ng/ml NGF, 1:100 matrigel), with 72 hr media changes. Morphologically neuronal cells comprised approximately 80% of the cultures.

Drug treatments

To generate expression profiles of different drug class treatments, twenty antidepressants (five selective serotonin reuptake inhibitor, four serotonin receptor agonists, seven monoamine oxidase inhibitor, three norepinephrine uptake inhibitors), eight antipsychotics (four classic neuroleptics, four atypical antipsychotics) and eight opioid receptor agonists (two delta receptor agonists, three mu receptor agonists, three kappa receptor agonists) were administered to primary human neuronal cultures. Drugs used for treatment were dissolved in DMSO and added to cultures to achieve a final DMSO concentration of 0.04%. Final drug concentrations represented

pharmaceutically relevant doses: amoxepine, 2.0 μ M; clomipramine, 2.0 μ M; desipramine, 2.0 μ M; doxepin, 1.0 μ M; imipramine, 2.0 μ M; maprotiline, 1.0 μ M; nortriptyline, 0.7 μ M; protriptyline, 0.4 μ M; trimipramine, 1.5 μ M; citalopram, 0.3 μ M; paroxetine, 0.3 μ M; sertraline, 1.4 μ M; tranylcypromine, 0.4 μ M; phenylzine, 0.8 μ M; iproniazid, 0.6 μ M; trazadone, 2.0 μ M; amitriptyline, 1.0 μ M; fluoxetine, 0.5 μ M; fluvoxamine, 1.5 μ M; bupropion, 2.3 μ M; chlorpromazine, 1.0 μ M; trifluperazine, 1.0 μ M; triflupromazine, 0.8 μ M; pimozide, 0.05 μ M; clozapine, 4.0 μ M, haloperidol, 0.2 μ M; risperidone, 0.04 μ M; loxapine, 0.5 μ M; BW373U86, 0.1 nM; Enkephalin, 1.0 μ M; U50488, 0.1 nM; U62066, 1.0 μ M; Endomorphin, 1.0 μ M; DALDA, 0.1; DAMGO, 0.1 μ M; Dynorphin A, 0.1 μ M. All treatments were 24 hrs in duration and were conducted simultaneously. All drugs were purchased from Sigma-Aldrich (St. Louis, MO) or Tocris Cookson (Ellisville, MO).

Sample processing

Drug-treated cell cultures were lysed in Trizol. Total RNA was extracted by phenol chloroform extraction. Each sample evaluated for gene expression by hybridization to the proprietary CuraChip microarray (CuraGen, New Haven, CT) of approximately 11,000 oligonucleotide probes corresponding to the component of the human genome encoding proteins with activities in classes targetable by pharmaceutical means (the “pharmaceutically tractable genome”). Biotin-labeled cDNA was made using 15ug of total RNA using poly-T oligo primers. Slides were hybridized at 30°C for 15 hours with constant rotation, then washed for 30 min at RT. Slides were incubated in streptavidin solution (4°C, 30 min) and washed 3X for 15 min at RT, followed by incubation in Cy3-conjugated detection buffer (4°C, 30 min) and again washed 3X for 15 min at RT. Slides were then scanned (GMS 418 Scanner, Genetic Microsystems, Woburn, MA) and images analyzed using Imagen software (BioDiscovery, Marina Del Rey, CA). Of the 11,000 genes on the microarray, approximately 4,700 were found to be expressed by primary human neuronal cultures at three-fold above background.

EXAMPLE 2: IDENTIFICATION OF GENES ASSOCIATED WITH PSYCHOACTIVE COMPOUNDS

All genes detectable at three-fold over background after signal normalization were included in the data sets for analysis. Data was pre-filtered using a generous Kruskal-Wallis filter ($p < 0.001$, ~4700 genes over 36 samples). Classification Trees were calculated within a leave one out cross-validation loop to minimize the influence of marker pre-filtering on model accuracy. The markers selected for the decision tree were then removed from the data set and this process was repeated two additional times. For each iteration of the classification tree algorithm, the samples were weighted

such that an unknown would have an equal probability of falling within either class, and not default to the over represented class (antidepressants). The Random Forest algorithm was also calculated within a leave one out cross-validation loop using pre-filtered data, with 1000 trees grown and 2 random inputs attempted at each split. All statistical algorithms were performed using the ‘R’ statistical software system (<http://www.cran.r-project.org/>). The result of this process is the identification of a set of biomarker genes for the defined drug classes. (Table 4)

Supervised Classification of Drug-Treated Samples

The supervised classification methods of Random Forest and Classification Tree were used to analyze the gene expression profiles of drug-treated neurons, as has been described previously¹⁹. These methods have the advantage that examples of known classes can be used to build models of salient features that provide categorical distinction between the data sets used to build the models. These models can be tested empirically with data sets of known class that were not used in model construction (cross validation). With both the Classification Tree and Random Forest methods, a “leave one out” training and testing series was conducted for all 36 drug treated samples. Thus, 36 individual models were constructed, each trained with 35 example gene expression profiles, with one profile withheld from training for evaluation. After construction of each model, the profile excluded from the training set was tested by the model for assignment to one of the three drug treatment categories (antidepressant, antipsychotic or opioid receptor agonist). The overall effectiveness of each method was calculated as the percent correct classifications out of the total 36 training and testing events conducted by the method.

Classification Tree

The Classification Tree method classified 32 out of 36 expression profiles in the category corresponding to the therapeutic application of the drug used to treat the cells (88.9% correct classification) (Table. 2). Of the 20 antidepressants, 18 were correctly classified, one was classified as an antipsychotic and one was classified as an opioid receptor agonist. Of the eight antipsychotics, seven were correctly classified and one was classified as an antidepressant. Of the eight opioid receptor agonists, seven were correctly classified and one was classified as an antidepressant. Interestingly, as few as four gene markers were sufficient to provide this level of resolution accuracy among these expression profiles. The identity of these genes is: PTX3 (pentaxin 3), ILK (integrin linked kinase), ENTPD6 (ectonucleoside triphosphate diphosphohydrolase 6), and a novel G protein-coupled receptor, GPCR CG50207. PTX3 (pentaxin 3) and ILK (integrin linked kinase) were sufficient to provide the majority of resolution between classes, as indicated by the high marker count for these genes (Table 3). Three-dimensional graphical representation of all possible

three-way combinations of these four biomarkers illustrates the robust class separation provided by expression level comparison

Table 2 : Classification of gene expression profiles induced by different drug treatments.

5	Compound	"True" Class	Classification Tree Prediction	Random Forest Prediction	Functional Subclass
	amoxapine	AD	AD	AD	tricyclic (NE, 5HT)
	clomipramine	AD	AD	AD	tricyclic (5HT, NE)
10	desipramine	AD	OP	AD	tricyclic (NE)
	doxepin	AD	AD	AD	tricyclic (NE, 5HT)
	imipramine	AD	AD	AD	tricyclic (5HT, NE)
	maprotiline	AD	AD	AD	tricyclic (NE)
	nortriptyline	AD	AD	AD	tricyclic (NE, 5HT)
15	protriptyline	AD	AD	AD	tricyclic (NE, 5HT)
	trimipramine	AD	AD	AD	tricyclic (NE, 5HT)
	amitriptyline	AD	AD	AD	tricyclic (5HT, NE)
	citalopram	AD	AD	AD	SSRI
	paroxetine	AD	AD	AD	SSRI
20	sertraline	AD	AD	AD	SSRI
	fluoxetine	AD	AD	AD	SSRI
	fluvoxamine	AD	AD	AD	SSRI
	tranylcypromine	AD	AD	AD	MAOI
	phenylzine	AD	AP	AP	MAOI
25	iproniazid	AD	AD	AP	MAOI
	trazadone	AD	AD	AD	atypical (5HT)
	bupropion	AD	AD	AD	atypical (5HT, NE)
	chlorpromazine	AP	AP	AP	classic AP
	trifluoperazine	AP	AP	AP	classic AP
30	triflupromazine	AP	AP	AP	classic AP
	pimozide	AP	AP	AP	classic AP
	clozapine	AP	AD	AD	atypical AP
	haloperidol	AP	AP	AP	atypical AP
	risperidone	AP	AP	AP	atypical AP
35	loxapine	AP	AP	AD	atypical AP
	BW373U86	OP	OP	AD	δ OPR
	Enkephalin	OP	AD	AD	δ OPR
	U50488	OP	OP	OP	κ OPR
	U62066	OP	OP	OP	κ OPR
40	Endomorphin	OP	OP	OP	κ OPR
	DALDA	OP	OP	OP	μ OPR
	DAMGO	OP	OP	OP	μ OPR
	Dynorphin A	OP	OP	AD	μ OPR
45	% "correct"		88.9	83.3	

"True" Class = the known therapeutic utility of each drug; AD = antidepressant; AP = antipsychotic; OP = opioid receptor agonist. Designations under the Classification Tree and Random Forest headings are the classes predicted by those methods for the expression profiles elicited by the drugs on the left. Shaded designations indicate predicted therapeutic classes different from the "true" class. MAOI = monoamine oxidase inhibitor; δ OPR = delta opioid receptor; κ OPR = kappa opioid receptor; μ OPR = mu opioid receptor; SSRI = selective serotonin reuptake inhibitor; (NE) or (5HT) = amine selectivity; (NE, 5HT) = both amines affected, in order of selectivity.

Table 3 Marker sets resulting from three sequential iterations of the
Classification Tree analysis method

Iteration 1	
Marker identity	Marker count
PTX3 pentaxin 3	35
ILK integrin linked kinase	34
ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6	1
GPCR CG50207	1

5

Iteration 2	
Marker identity	Marker count
SFRS7 splicing factor, arginine/serine-rich 7	34
ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6	24
CBRC7TM_424 GPCR	1
APAFf-1apoptotic protease activating factor 1	1
ERMAP erythroblast membrane-associated protein	8
CGFLC_31120	1
GPCR CG50207	1
LDHA Lactate dehydrogenase A	1

Iteration 3	
Marker identity	Marker count
LYPLA1 lysophospholipase 1	34
GPCR CG50207	26
CBRC7TM_424 GPCR	1
APAFf-1apoptotic protease activating factor 1	8
CGFLC_31120	1
LDHA Lactate dehydrogenase A	1

- 10 For each iteration, the two most frequent markers from the previous iteration were deleted from the expression data set. Marker identities are given where possible; GPCR CG50207 and CGFLC_31120 are novel sequences of GPCR and unknown function, respectively. Marker count represents the number of times out of the 36 model building episodes a particular gene was selected as a marker.

15 *Random Forest*

- 20 The Random Forest method classified 30 out of 36 expression profiles in the category corresponding to the therapeutic application of the drug used to treat the cells (83.3% correct classification) (Table 2). Of the 20 antidepressants, 18 were correctly classified and two were classified as antipsychotics. Of the eight antipsychotics, seven were correctly classified and one was classified as antidepressant. Of the eight opioid receptor agonists, five were correctly classified and three were classified as antidepressants. The Random Forest analysis identified 326 markers that were used to construct the predictive models. The markers assumed an importance measure between zero and one, relating to the strength of their respective contributions to the models. A large

importance measure indicates that random permutation of that gene causes samples to be misclassified more often (hence that gene is important). 32 of the markers had an importance measure greater than 0.35. Three had an importance measure above 0.75: SFRS7 (splicing factor, arginine/serine-rich 7), SCG3 (secretogranin III), and hypothetical protein CG187232-01. The class separation provided by only these three top biomarkers is less distinct than the separation yielded by the biomarkers identified by the Classification Tree. This is probably due to the relative proficiency of the Classification Tree and Random Forest algorithms with data sets containing a few strong markers, or a large number of weak markers, respectively.

Multiple Iterations of Classification Tree

Since relatively few genes were identified as drug class markers by the Classification Tree, we investigated the robustness of the approach in the absence of these markers by successively performing a second and third iteration of the analysis, excluding from the data set the predominant gene markers identified by the first and second iterations, respectively (Table 4). The second iteration resulted in the identification of eight gene markers sufficient to provide 72.2% resolution accuracy. Interestingly, the third iteration resulted in the identification of fewer gene markers (six) than the second iteration, sufficient to provide greater resolution accuracy (80.6%) between treatment classes, even though the strongest markers from the second iteration were removed from the data set.

Table 4. Drug class predictions resulting from three sequential iterations of the Classification Tree analysis method

Compound	"True" Class	Iteration 1	Iteration 2	Iteration 3
amoxapine	AD	AD	AD	AD
clomipramine	AD	AD	AP	AP
desipramine	AD	OP	AD	AD
doxepin	AD	AD	AD	AD
imipramine	AD	AD	AD	AD
maprotiline	AD	AD	AD	AD
nortriptyline	AD	AD	AD	AD
protriptyline	AD	AD	AD	AD
trimipramine	AD	AD	AD	AD
amitriptyline	AD	AD	AD	AD
citalopram	AD	AD	AD	AD
paroxetine	AD	AD	OP	AD
sertraline	AD	AD	AD	AD
fluoxetine	AD	AD	AD	AD
fluvoxamine	AD	AD	AD	AD
tranylcypromine	AD	AD	AD	AD
phenylzine	AD	AP	AP	AP
iproniazid	AD	AD	AP	AP
trazadone	AD	AD	AD	AD

	bupropion	AD	AD	AP	AD
	chlorpromazine	AP	AP	AP	AP
	trifluoperazine	AP	AP	AD	AP
	triflupromazine	AP	AP	AP	AP
5	pimozide	AP	AP	AP	AP
	clozapine	AP	AD	AD	AD
	haloperidol	AP	AP	AP	AP
	risperidone	AP	AP	AP	AP
	loxapine	AP	AP	AP	AP
10	BW373U86	OP	OP	OP	OP
	Enkephalin	OP	AD	AD	AD
	U50488	OP	OP	OP	OP
	U62066	OP	OP	OP	OP
	Endomorphin	OP	OP	OP	OP
15	DALDA	OP	OP	AD	OP
	DAMGO	OP	OP	OP	OP
	Dynorphin A	OP	OP	AD	AD
	% "correct"	88.9	72.2	80.6	

20 The two most frequent markers from the previous iteration deleted from the data set for subsequent iterations.
 "True" Class = the known therapeutic utility of each drug; AD = antidepressant; AP = antipsychotic; OP = opioid
 25 receptor agonist. Designations under the Classification Tree and Random Forest headings are the classes predicted by
 those methods for the expression profiles elicited by the drugs on the left. Shaded designations indicate predicted
 therapeutic classes different from the "true" class.

Table 5 summarizes the expression level range in the form of relative fluorescence units (RFU), for each biomarker required for effective categorization to occur.

30 Table: 5

Genes	Max AD	Min AD	Max AP	Min AP	Max OP	Min OP
PTX3 pentaxin 3	1.081475	0.688761	1.036963	0.601615	1.696653	1.086105
ILK integrin linked kinase	1.276744	0.764877	0.915803	0.739284	1.175496	0.858477
ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6	1.549311	0.786736	1.076364	0.573707	1.477081	0.837467
GPCR CG50207	1.826622	0.852346	1.321024	0.493227	1.464915	0.339308
SFRS7 splicing factor, arginine/serine-rich 7	1.12308	0.5331	1.0783	0.687398	1.359178	1.123489
CBRC7TM_424 GPCR	1.600307	0.067351	2.401118	1.036077	0.938608	0.497713
APAF-1 apoptotic protease activating factor 1	1.680057	0.696118	0.905628	0.606785	1.299162	0.81503
ERMAP erythroblast membrane-associated protein	1.241793	0.449553	1.591711	1.194523	1.28326	0.427542
CGFLC_31120	1.152633	0.659439	1.750288	0.908919	1.45432	0.664492
LYPLA1 lysophospholipase I	1.195241	0.394012	1.274685	0.672949	1.986995	1.328546
LDHA Lactate dehydrogenase A	1.182659	0.420308	1.218164	0.588735	1.725345	1.116754
SCG3	1.198662	0.343028	0.984209	0.602056	1.482699	1.179987
CG187232	1.401032	0.338927	0.91906	0.369117	2.340879	0.824419

EXAMPLE 3: PSYCHOACTIVE-ASSOCIATED GENES

5

This example provides exemplary PSYCHMARKER nucleic acid sequences, useful in methods of screening compounds for psychoactive activity according to the invention

PTX3 pentaxin 3 (PSYCHMARKER 1 ; SEQ ID NO :1)

10 ATGCATCTCC TTGCGATTCT GTTTTGTGCT CTCTGGTCTG CAGTGTGTCG CGAGAATCG
GATGATTATG ATCTCATGTA TGTGAATTTG GACAACGAAA TAGACAATGG ACTCCATCCC
ACTGAGGACC CCACGCCGTG CGACTGCGGT CAGGAGCACT CGGAATGGGA CAAGCTCTTC
ATCATGTGG AGAACTCGCA GATGAGAGAG CGCATGCTGC TGCAAGCCAC GGACGACGTC
15 CTGCGGGGCG AGCTGCAGAG GCTGCGGGAG GAGCTGGGCC GGCTCGCGGA AAGCCTGGCG
AGGCCGTGCG CGCCGGGGGC TCCCGCAGAG GCCAGGCTGA CCAGTGTCTT GGACGAGCTG
CTGCAGGCGA CCCGCGACGC GGGCCGCGAG CTGGCGCGTA TGGAGGGCGC GGAGGCGCAG
CGCCAGAGG AGGCGGGGCG CGCCCTGGCC GCGGTGCTAG AGGAGCTGCG GCAGACGCGA
GCCGACCTGC ACGCGGTGCA GGGCTGGGCT GCCCGGAGCT GGCTGCCGGC AGGTGTGTAA
ACAGCTATTT TATTCCCAAT GCGTTCCAAG AAGATTTTTG GAAGCGTGCA TCCAGTGAGA
20 CCAATGAGGC TTGAGTCTTT TAGTGCCTGC ATTTGGGTCA AAGCCACAGA TGTATTAAAC
AAAACCATCC TGTTTTCTTA TGGCACAAAG AGGAATCCAT ATGAAATCCA GCTGTATCTC
AGCTACCAAT CCATAGTGTT TGTGGTGGGT GGAGAGGAGA ACAAATGGT TGCTGAAGCC
ATGTTTTCCC TGGGAAGGTG GACCCACCTG TGCGGCACCT GGAATTCAGA GGAAGGGCTC
ACATCCTTGT GGGTAAATGG TGAAC TGGCG GCTACCAC TG TAGATGGC CACAGGTCAC
25 ATTGTTCTTG AGGGAGGAAT CCTGCAGATT GGCCAAGAAA AGAATGGCTG CTGTGTGGGT
GGTGGCTTTG ATGAAACATT AGCCTTCTCT GGGAGACTCA CAGGCTTCAA TATCTGGGAT
AGTGTCTTA GCAATGAAGA GATAAGAGAG ACCGGAGGAG CAGAGTCTTG TCACATCCGG
GGGAATATTG TTGGGTGGGG AGTCACAGAG ATCCAGCCAC ATGGAGGAGC TCAGTATGTT
TCATAA

30

ILK integrin linked kinase (PSYCHMARKER 2 ; SEQ ID NO :2)

35 TTTTTTTTTTTTTTTTTTTTTTTCATAATAAACTTTATTGTGACAGGCGGGGCTGATCCCT
CCCATGTTGGAAGACACCATGTGGCAAGTGACAAAGCTCTGAGCCCGCCCCCTTTGCGCA
CAGTGGTAGGGATGGGGGAAGGGGATGGACCCAGGCTGGGGTAGTACCATGACTGGAGG
CGGGGGAGGCAACCAGAGGCCGTGCTGCTTTGGGGAGGTGCATTTCCCCCAACCATGTCCCG
ACACCTCTGGAGTTCAGGCAAGGACCTTCCAGTCTTACTTGTCTGCATCTTCTCAAGGA
40 TAGGCACAATCATGTCAAATTTGGGTGCTTTGTCAGGGTCTTCATTTCATGCAGATCTTCA
TGAGCTTACACACATGAGGGGAAATACCTGGTGGGATGGTAGGCCGAAGGCCCTTCCAATG
CCACCTTCATTCCAATCTCCATATTGGAGAGGTGAGCAAAGGGTACCTCCCGTGTACCA
GTTCCACAGAAAGCACTGCAAACTCCACATGTCTGCTGAGCGTCTGTTTGTGTCTTCAG
GCTTCTTCTGCAGAGCTTCGGGGGCTACCCAGGCAGGTGCATACATGCGACCAGGACATT
45 GGAAAGAGAACTTGACATCAGCCATGCTAATTCGGGCAGTCATGTCTCATCAATCATTA
CACTACGGCTATTGAGTGCATGTGCTGGGATGAGGGGCTCTAGTGTGTGTAGGAAGGCCA
TGCCCCCTTGCCATGTCCAAAGCAAACCTTCACAGCCTGGCTCTGGTCCACGACGAAATTGG
TGCCCTTCATGTAGTACATTGTAGAGGGATCCATACGGCATCCAGTGTGTGATGAGAGTAG
GATGAGGAGCAGGTGGAGACTGGCAGGCACCTAGCACTGGGAGCACATTTGGATGCGAGA
50 AAATCCTGAGCCGGGACACTCTTCATTGAAGTCCCTGCTCTTCTTGTACTCCAGTCTC
GAACCTTCAGCACCTTCACGACAATGTTCATTGCCCTGCCAGCGGCCCTTCCATAGCTCTC
CAGAGTGATTCTCGTTGAGCTTCGTCAGGAAGTTAAGCTGTTTGAAGTCAATGCCAGAGT
GTTTGTTCAGGGTTCCATTTCGGGGCCGAGGTGCGGGTGGTCCCTTCCAGAAATGTGTCCT
TGTATGGAATACGGTTGAGATTCTGGCCCATCTTCTCTGCCCGCTCTCGGAGAAGCTCTC
55 TCAGGGGTGCCCTTGGCTTTGTCCACAGGCATCTCTCCATACTTGTACAGATGCTGACAA

GGGCCCCATTTGCCACCAGGTCTCTGCCACTTGATCTTGGCCCCAAAAACAGGCATAGT
GCAGGGGCACATTCCCGTGTTTCATTCACTGCATTGATGTCTGCCCTTGTAAGTCAATAGCT
TCTGTACAATATCACGGGTGTCCATGACTGGCTGCCAGATGCAGGGGGGTGTATCCCCAC
GGTTCATTACATTGATCCCGTGCCCCCGCATGATCAACATCTCAACCACAGCAGAGCGGC
5 CCTCTCGGCAGGCCCAGTGCAAGGGGGAGAAGCCATGATCGTCCCCCTGGTTGAGGTCTGT
TCTCCGTGTTGTCCAGCCACAGGCGAACGGCGACTGCGTTGCCCTCCCGGCAGTGAAGTGA
AAATGTCGTCCATAGCAGCGTCCCGGCGCCGAGTCCCCTGGATTGGGGAAGCCTGAGGAC
TGTGGAGTGATCCAGGGAAGGAGGATGAACCCCAAGCTTTATCCTCGGGACTCGGGCTGC
AGGATCCTTCTCCGGGGAACCTCCCGTGGTAGCAGTCGACAGATGAATTC

ENTPD6 (Ectonucleoside triphosphate diphosphohydrolase 6)
(PSYCHMARKER 3 ; SEQ ID NO :3)

CCCACCATGAAAAAAGGTATCCGTTATGAAACTTCCAGAAAAACGAACTACATTTTTTCAG
CAGCCGCAGCACGGTCTTGGCAAACAAGGATGAGAAAAATATCCAACCACGGGAGCCTG
CGGGTGGCGAAGGTGGCATACCCCCCTGGGGCTGTGTGTGGGCGTGTTCATCTATGTTGCC
TACATCAAGTGGCACCGGGCCACCGCCACCCAGGCCCTTCTTCAGCATCACCAGGGCAGCC
CCGGGGGCCCCGGTGGGGTTCAGCAGGCCACAGCCCCCTGGGGACAGCTGCAGACGGGCAC
20 GAGGTCTTCTACGGGATCATGTTTGTATGCAGGAAGCACTGGCACCCGAGTACACGTCTTC
CAGTTCCACCCGGCCCCCAGAGAACTCCCACGTTAACCACGAAACCTTCAAAGCACTG
AAGCCAGGTCTTCTGCCTATGCTGATGATGTTGAAAAGAGCGCTCAGGGAATCCGGGAA
CTACTGGATGTTGCTAAACAGGACATTCCATTGACTTCTGGAAGGCCACCCCTCTGGTC
CTCAAGGCCACAGCTGGCTTACGCCTGTTACCTGGAGAAAAGGCCCAGAAGTTACTGCAG
25 AAGGTGAAAGAAGTATTTAAAGCATCGCCTTTCCTTGTAGGGGATGACTGTGTTTCCATC
ATGAACGGAACAGATGAAGGCGTTTCGGCGTGGATCACCATCAACTTCCTGACAGGCAGC
TTGAAAACCTCCAGGAGGGAGCAGCGTGGGCATGCTGGACTTGGGCGGAGGATCCACTCAG
ATCGCCTTCTTCCAGCGCTGGAGGGCACCCTGCAGGCCCTCCCAACCCGGCTACCTGACG
GCATGCGGATGTTTAAACAGGACCTACAAGCTCTATTCTTACAGCTACCTCGGGCTCGGG
30 CTGATGTCGGCACGCGCTGGCGATCCTGGGCGGCGTGGAGGGGCAGCCTGCTAAGGATGGA
AAGGAGTTGGTCAGCCCTTGCTTGTCTCCAGTTTCAAAGGAGAGTGGGAACACGCAGAA
GTCACGTACAGGGTTTCAGGGCAGAAAGCAGCGGCAAGCCTGCACGAGCTGTGTGCTGCC
AGAGTGTACAGAGTCTTCAAACAGAGTGCACAGGACGGAGGAAGTGAAGCATGTGGAC
TTCTATGCTTTCTCCTACTATTACGACCTTGCAGCTGGTGTGGGCTCATAGATGCGGAG
35 AAGGGAGGCAGCCTGGTGGTGGGGGACTTCGAGATCGCAGCCAAGTACGTGTGTGCGACC
CTGGAGACACAGCCGACAGCAGCCCCCTTCTCATGCATGGACCTCACCTACGTGAGCCTG
CTACTCCAGGAGTTTCGGCTTTCCAGGAGCAAAGTGCTGAAGCTCACTCGGAAAATTGAC
AATGTTGAGACCAGCTGGGCTCTGGGGGCCATTTTTTCATTACATCGACTCCCTGAACAGA
CAGAAGAGTCCAGCCTCA

CG50207 (GPCR) (PSYCHMARKER 4 ; SEQ ID NO :4)

ATGACGAACACATCATCCTCTGACTTCACCCCTCCTGGGGCTTCTGGTGAACAGTGAGGCT
45 GCCGGGATTTGATTTACAGTGATCCTTGCTGTTTTCTTGGGGGCCGTGACTGCAAATTTG
GTCATGATATTTGATTCAGGTGGACTCTCGCCTCCACACCCCCATGTACTTTCTGCTC
AGTCAGCTGTCCATCATGGACACCCTTTTTCATCTGTACCACTGTCCCAAACTCCTGGCA
GACATGGTTTCTAAAGAGAAGATCATTTCTTTGTGGCCTGTGGCATCCAGATCTTCCTC
TACCTGACCATGATTGGTTCTGAGTTCTTCTCCTGGGCCCTCATGGCCTATGACCGCTAC
50 GTGGCTGTCTGTAAACCTCTGAGATACCCAGTCCGTGATGAACCGCAAGAAGTGCTTTTG
CTGGCTGTCTGCTTGGTTTGGGGGCTCCCTCGATGGCTTTCTGCTCACTCCCATCACC
ATGAATGTCCCTTACTGTGGCTCCCGAAGTATCAACCAATTTTTCTGTGAGATCCAGCA
GTTCTGAAACTGGCCTGTGCAGACACGTCTTGTATGAACTCTGATGTACATCTGCTGT
GTCCTCATGTTGCTCATCCCCATCTCTATCATCTCCACTTCCCTACTCCCTCATCTTGTTA
55 ACCATCCACCGCATGCCCTCTGCTGAAGGTGCAAAAAGGCCCTTCAACCACTTGTTCCTCC
CACTTGACTGTAGTTAGCATCTTCTATGGGGCTGCCCTTCTACACATACGTGCTGCCCCAG
TCCTTCCACACCCCCGAGCAGGACAAAGTAGTGTGAGCCTTCTATACCATTTGTACGCCC
ATGCTTAATCCTCTCATCTACAGCCTCAGAAACAAGGACGTATAGGGGCATTTAAAAAG
GTATTTGCATGTTGCTCATCTGCTCGGAAAGTAGCAACAAGTGATGCTTAGAGAGTCACT

CCCCAGAGGATAAGGCTTCCTAAGGACTTCCTC

SFRS7 (splicing factor, arginine/serine-rich 7)

5 **(PSYCHMARKER 5 ; SEQ ID NO :5)**

GTAGTGCCGCCGGGACTCTTGGCGGGTGAAGGTGTGTGTCAGCTTTTGCGTCACTCGAGC
CCTGGGCGCTGCTTGCTAAAGAGCCGAGCACGCGGGTCTGTATCATGTGCGGTTACGGG
10 CGGTACGGAGGAGAAACCAAGGTGTATGTTGGTAACCTGGGAAGTGGCGCTGGCAAAGGA
GAGTTAGAAAGGGCTTTTCAGTTATTATGGTCCTTTAAGAACTGTATGGATTGCGAGAAAT
CCTCCAGGATTTGCCCTTTGTGGAATTCTGAAGATCCTAGAGATGCAGAAGATGCAGTACGA
GGACTGGATGGAAAGGTGATTTGTGGCTCCCGAGTGAGGGTTGAACTATCGACAGGCATG
CCTCGGAGATCACGTTTTGATAGACCACCTGCCCGACGTCCCTTTGATCCAAATGATAGA
15 TGCTATGAGTGTGGCGAAAAGGGACATTATGCTTATGATTGTTCATCGTTACAGCCGGCGA
AGAAGAAGCAGGTACGGTCTAGATCACATTCTCGATCCAGAGGAAGGCGATACTCTCGC
TCACGCAGCAGGAGCAGGGGACGAAGGTCAAGGTGAGCATCTCCTCGACGATCAAGATCT
ATCTCTCTTCGTAGATCAAGATCAGCTTCACTCAGAAGATCTAGGTCTGGTTCTATAAAA
GGATCGAGGTATTTCCAATCCCCGTCGAGGTCAAGATCAAGATCCAGGTCTATTTACGA
20 CCAAGAAGCAGCCGATCAAAGTCCAGATCTCCATCTCCAAAAGAAGTCGTTCCCATCA
GGAAGTCCTCGCAGAAGTGCAAGTCCTGAAAGAATGGACTGAAGCTCTCAAGTTCACCCCT
TTAGGGAAAAGTTATTTTGTGTTTACATTATTATAAGGGATTTGTGATGTCTGTAAAGTGTA
ACCTAGGAAAGATAATTCAACCATCTAATCAAAATGGATCTGGATTACTATGTAAATTCA
CAGCAGTAAGG

25

CBRC7TM 424 GPCR (PSYCHMARKER 6 ; SEQ ID NO :6)

ATGGATCAGA GAAATTACAC CAGAGTGAAA GAATTTACCT TCCTGGGAAT TACTCAGTCC
30 CGAGAACTGA GCCAGGTCTT ATTTACCTTC CTGTTTTTGG TGTACATGAC AACTCTAATG
GGAAACTTCC TCATCATGGT TACAGTTACC TGTGAATCTC ACCTTCATAC GCCCATGTAC
TTCTGTCTCC GCAACCTGTC TATTCTTGAC ATCTGCTTTT CCTCCATCAC AGCTCCTAAG
GTCTGTATAG ATCTTCTATC AGAGACAAAA ACCATCTCCT TCAGTGGCTG TGTCACTCAA
ATGTTCTTCT TCCACCTTCT GGGGGGAGCA GACGTTTTTT CTCTCTCTGT GATGGCGTTT
35 GACCGCTATA TAGCCATCTC CAAGCCCCTG CACTATATGA CCATCATGAG TAGGGGGCGA
TGCACAGGCC TCATCGTGGC TTTCTGGGTG GGGGGCTTTG TCCACTCCAT AGCGCAGATT
TCTCTATTGC TCCCACTCCC TTTCTGTGGA CCCAATGTTT TTGACACTTT CTACTGCGAT
GTCCCCCAGG TCCTCAAAT TGCCTGCACT GACACCTTCA CTCTGGAGCT CCTGATGATT
TCAAATAATG GGTTAGTCAG TTGGTTTGTA TTCTTCTTTC TCCTCATATC TTACACGGTC
40 ATCTTGATGA TGCTGAGGTC TCACACTGGG GAAGGCAGGA GGAAAGCCAT CTCCACCTGC
ACCTCCACA TCACCGTGGT GACCCTGCAT TTCGTGCCCT GCATCTATGT CTATGCCCGG
CCCTTCACTG CCCTCCCCAC AGACACTGCC ATCTCTGTCA CCTTCACTGT CATCTCCCTT
TTGCTCAATC CTATAATTTA CACGCTGAGG AATCAGGAAA TGAAGTTGGC CATGAGGAAA
CTGAAGAGAC GGCTAGGACA ATCAGAAAGG ATTTTAATTC AATAA

45

APAF-1 (apoptotic protease activating factor 1)

(PSYCHMARKER 7 ; SEQ ID NO :7)

AAGAAGAGGTAGCGAGTGGACGTGACTGCTCTATCCCGGGCAAAGGGATAGAACCAGAG
50 GTGGGGAGTCTGGGCAGTCGGCGACCCGCGAAGACTTGAGGTGCCGCAGCGGCATCCGGA
GTAGCGCCGGGCTCCCTCCGGGGTGACCCGCCGTGCGGGGAAGGGCGCCACAGGCCGGG
AAGACCTCCTCCCTTTGTGTCCAGTAGTGGGGTCCACCGGAGGGCGGCCCGTGGGCCGGG
CCTCACCGCGGCGCTCCGGGACTGTGGGGTCAGGCTGCGTTGGGTGGACGCCACCTCGC
CAACCTTCGGAGGTCCCTGGGGTCTTCGTGCGCCCCGGGGCTGCAGAGATCCAGGGGAG
55 GCGCCTGTGAGGCCCGGACCTGCCCCGGGGCGAAGGGTATGTGGCGAGACAGAGCCCTGC
ACCCCTAATTTCCCGGTGGAAGTCCCTGTTGCCGTTTCCCTCCACCGGCCTGGAGTCTCC
CAGTCTTGTCCCGGCAGTGCCGCCCTCCCACTAAGACCTAGGCGCAAAGGCTTGCTCA
TGGTTGACAGCTCAGAGAGAGAAAGATCTGAGGGAAGATGGATGCAAAGCTCGAAATTG

TTTGCTTCAACATAGAGAAGCTCTGGAAAAGGACATCAAGACATCCTACATCATGGATCA
 CATGATTAGTGATGGATTTTTTAACAATATCAGAAGAGGAAAAAGTAAGAAATGAGCCAC
 TCAACAGCAAAGAGCAGCTATGCTGATTAAATGATACTTAAAAAGATAATGATTCTTA
 CGTATCATTCTACAATGCTCTACTACATGAAGGATATAAAGATCTTGCTGCCCTTCTCCA
 5 TGATGGCATTCTGTGTCTCTTCTTCCAGTGTAAGGACAGTCCTGTGTGAAGGTGGAGT
 ACCACAGAGGCCAGTTGTTTTTGTCAAGGAAGAAGCTGGTGAATGCAATTCAGCAGAA
 GCTCTCCAAATTGAAAGGTGAACCAGGATGGGTCAACATACATGGAATGGCAGGCTGTGG
 GAAGTCTGTATTAGCTGCAGAAGCTGTTAGAGATCATTCCCTTTTAGAAGGTGTTTCCC
 10 AGGGGGAGTGCATTGGGTTTTAGTTGGGAAAACAAGACAAATCTGGGCTTCTGATGAACT
 GCAGAATCTTTGCACACGGTTGGATCAGGATGAGAGTTTTTCCCAGAGGCTTCCACTTAA
 TATTGAAGAGGCTAAAGACCGTCTCCGCATTCTGATGCTTCGCAAACACCCAAGGTCTCT
 CTTGATCTTGGATGATGTTTTGGGACTCTTGGGTGTTGAAAGCTTTTGACAGTCAGTGTCA
 GATTCTTCTTACAACCAGAGACAAGAGTGTTACAGATTCAGTAATGGGTCTTAAATATGT
 AGTCCCTGTGGAGAGTTCCCTTAGGAAAAGGAAAAAGGACTTGAAATTTTATCCCTTTTTGT
 15 TAATATGAAGAAGGCAGATTTGCCAGAACAGCTCATAGTATTATAAAAAGAAATGTAAAGG
 CTCTCCCTTGTAGTATCTTTAATTGGTGCACTTTTTACGTGATTTTTCCCAATCGCTGGGA
 GTACTACCTCAAACAGCTTCAGAATAAGCAGTTTAAGAGAATAAGGAAATCTTCGTCTTA
 TGATTATGAGGCTCTAGATGAAGCCATGTCTATAAGTGTTGAAATGCTCAGAGAAGACAT
 CAAAGATTATTACACAGATCTTCCATCCTTCAGAAGGACGTTAAGGTGCCTACAAAGGT
 20 GTTATGTATTCTCTGGGACATGGAACTGAAGAAGTTGAAGACATACTGCAGGAGTTTGT
 AAATAAGTCTCTTTTTTCTGTGATCGGAATGGAAAGTCGTTTCGTTATTATTATACATGA
 TCTTCAAGTAGATTTTCTTACAGAGAAGAATTCAGCCAGCTTCAGGATCTACATAAGAA
 GATAATCACTCAGTTTTCAGAGATATCACCAGCCGCATACTCTTTCACCAGATCAGGAAGA
 CTGTATGTATTGGTACAACTTTTCTGGCCTATCACATGGCCAGTGCCAAGATGCACAAGGA
 25 ACTTTGTGCTTTAATGTTTTCCCTGGATTGGATTAAAGCAAAAACAGAACTTGTAGGCCC
 TGCTCATCTGATTATGAATTTGTGGAATACAGACATATACTAGATGAAAAGGATTGTGC
 AGTCAGTGAGAATTTTCAGGAGTTTTTATCTTTAAATGGACACCTTCTTGGACGACAGCC
 ATTTCTAATATTGTACAACCTGGGTCTCTGTGAGCCGGAACCTTCAGAAGTTTATCAGCA
 AGCTAAGCTGCAGGCCAAGCAGGAGGTGATAATGGAATGCTTTACCTGGAATGGATAAA
 30 CAAAAAAAACATCACGAATCTTCCCGCTTAGTTGTCCGCCCCCACACAGATGCTGTTTA
 CCATGCCTGCTTTTTCTGAGGATGGTCAGAGAATAGCTTCTTGTGGAGCTGATAAAACCTT
 ACAGGTGTTCAAAGCTGAAACAGGAGAGAACTTCTAGAAATCAAGGCTCATGAGGATGA
 AGTGCTTTGTTGTGCATTCTCTACAGATGACAGATTTATAGCAACCTGCTCAGTGGATAA
 AAAAGTGAAGATTGGAATTCATGACTGGGGAAC TAGTACACACCTATGATGAGCACTC
 35 AGAGCAAGTCAATTGCTGCCATTTACCAACAGTAGTCATCATCTTCTCTTAGCCACTGG
 GTCAAGTGACTGCTTCTCAAACCTTGGGATTTGAATCAAAAAGAATGTCGAAATACCAT
 GTTTGGTCATACAAATCAGTCAATCACTGCAGATTTTCACCAGATGATAAGCTTTTGGC
 TAGTTGTTTCAAGTCAATGGAACCTTAAAGCTTTGGGATGCGACATCAGCAAATGAGAGGAA
 AAGCATTAATGTGAAACAGTTCTTCCATAAATTTGGAGGACCTCAAGAGGATATGGAAGT
 40 GATAGTGAAGTGTTTCTGTTGCTGCTGATGGTGCAAGGATAATGGTGGCAGCAAAAAA
 TAAAATCTTTCTTTTTGACATTCTACTAGTGGCCTATTGGGAGAAATCCACACGGGCCA
 TCACAGCACCATCCAGTACTGTGACTTCTCCCCACAAAACCATTTGGCAGTGGTTGCTTT
 GTCCAGTACTGTGTAGAGTTGTGGAATACAGACTCACGTTCAAAGGTGGCTGATTGCAG
 AGGACATTTAAGTTGGGTTTATGGTGTGATGTTTTCTCCTGATGGATCATCATTTTTGAC
 45 ATCTTCTGATGACCAGACAATCAGGCTCTGGGAGACAAAGAAAGTATGTAAGAACTCTGC
 TGTAATGTTAAAGCAAGAAGTAGATGTTGTGTTTCAAGAAAATGAAGTGATGGTCCTTGC
 AGTTGACCATATAAGACGCTCTGCAACTCATTAATGGAAGAACAGGTGAGATTGATTATCT
 GACTGAAGCTCAAGTTAGCTGCTGTTGCTTAAAGTCCACATCTTCAGTACATTGCATTTGG
 AGATGAAAATGGAGCCATTGAGATTTTAGAACTTGTAAACAATAGAATCTTCCAGTCCAG
 50 GTTTCAGCACAAGAAAACCTGTATGGCACATCCAGTTCACAGCCGATGAGAAGACTCTTAT
 TTCAAGTTCGTATGATGCTGAAATTCAGGTATGGAATTTGGCAATTGGACAAATGTATCTT
 TCTACGAGGCCATCAGGAAACAGTGAAAGACTTTTAGACTCTTGAAAAATTCAGACTGCT
 TTCTTGGTCATTTGATGGAACAGTGAAGGTATGGAATATTATTACTGGAATAAAGAAAA
 55 AGACTTTGTCTGTACCAGGGTACAGTACTTTCTTGTGACATTTCTCACGATGCTACCAA
 GTTTTCATCTACCTCTGCTGACAAGACTGCAAAGATCTGGAGTTTTGATCTCCTTTTGGC
 ACTTCATGAATTGAGGGGCCACAACGGCTGTGTGCGCTGCTCTGCCTTCTCTGTGGACAG
 TACCTTCTGGCAACGGGAGATGACAATGGAGAAAATCAGGATATGGAATGTCTCAAACGG
 TGAGCTTCTTCATTTGTGTGCTCCGCTTTTCAGAAGAAGGAGCTGCTACCCATGGAGGCTG
 GGTGACTGACCTTTGCTTTTCTCCAGATGGCAAAATGCTTATCTCTGCTGGAGGATATAT

TAAGTGGTGGAAACGTTGTCACTGGGGAATCCTCACAGACCTTCTACACAAATGGAACCAA
 TCTTAAGAAAATACACGTGTCCCTGACTTCAAAACATATGTGACTGTGGATAATCTTGG
 TATTTTATATATTTTACAGACTTTAGAAATAAAATAGTTAAGCATTAAATGTAGTTGAACTT
 TTTAAATTTTGAATTGGAAAAAATTCTAATGAAACCCTGATATCAACTTTTTATAAAG
 5 CTCTTAATTGTTGTGCAGTATTGCATTCAATACAAAAGTGTGTTGTGGTTGGATGAATAAT
 ATTAATGTAGCTTTTCCCAAATGAACATACCTTTAATCTTGTGTTTTTCATGATCATCATT
 AACAGTTTGTCTTAGGATGCAAATGAAAATGTGAATACATACCTTGTGTACTGTTGGT
 AAAATTCTGTCTTGATGCATTCAAAATGGTTGACATAATTAATGAGAAGAATTTGGAAGA
 AATTGGTATTTTAATACTGTCTGTATTTATTACTGTTATGCAGGCTGTGCCTCAGGGTAG
 10 CAGTGGCCTGCTTTTTGAACCACACTTACCCCAAGGGGGTTTTGTTCTCCTAAATACAAT
 CTTAGAGGTTTTTGCACCTCTTAAATTTGCTTTAAAAATATTGTGTCTGTGTGCATAGT
 CTGCAGCATTTTCTTTAATTGACTCAATAAGTGAGTCTTGGATTTAGCAGGCCCCCCCCAC
 CTTTTTTTTTTGTTTTTGGAGACAGAGTCTTGCTTTGTTGCCAGGCTGGAGTGCAGTGGC
 GCGATCTCGGCTCACCACAATCGCTGCCCTCCTGGGTTCAAGCAATTCTCCTGCCCTCAGCC
 15 TCCCCGAGTAGCTGGGACTACAGGTGTGCGCACATGCCAGGCTAATTTTTGTATTTTTAGT
 AGAGACGGGGTTTTACCATGTTGGCCGGGATGGTCTCGATCTCTTGACCTCATGATCTAC
 CCGCCTTGGCCTCCCAAAGTGCTGAGATTACAGGCGTGAGCCACCGTGCTTGGCCAGGCC
 CCTTCTCTTTTAAATGGAGACAGGGTCTTGCACTATCACCCAGGCTGGAGTGCAGTGGCAT
 AATCATACCTCATTCAGCCTCAGACTCCTGGGTTCAAGCAATCCTCCTGCCCTCAGCCTC
 20 CCAAGTAGCTGAGACTGCAGGCACGAGCCACCACACCAGCTAATTTTTAAGTTTTCTTG
 TAGAGACAGGGTCTCACTATGTTGTCTAGGCTGGTCTTGAACCTCTTGGCCTCAAGTAATC
 CTCCTGCCTCAGCCTCCCAAAGTGTGGGATTGCAGATATGAGCCACTGGCCTGGCCTTC
 AGCAGTTCTTTTTGTGAAGTAAACCTTGATGTTGGAAAGAGTAGATTTTATTGGTCTAC
 CCTTTTCTCACTGTAGCTGCTGGCAGCCCTGTGCCATATCTGGACTCTAGTTGTCAGTAT
 25 CTGAGTTGGACACTATTCTGCTCCCTCTTGTCTTACATATCAGACTTCTTACTTGAA
 TGAAACCTGATCTTCTTAATCCTCACTTTTTTCTTTTTTAAAAAGCAGTTTCTCCACTG
 CTAAATGTTAGTCATTGAGGTGGGGCCAATTTAATCATAAGCCTTAATAAGATTTTTCT
 AAGAAATGTGAAATAGAACAATTTTCATCTAATTCATTACTTTTAGATGAATGGCATT
 GTGAATGCCATTCTTTAATGAATTTCAAGAGAATCTCTGGTTTTCTGTGTAATTCAG
 30 ATGAGTCACTGTAACCTCTAGAAGATTAACCTTCCAGCCAACCTATTTTCCCTTCCCTTGT
 CTCTCTCATCCTCTTTTCCCTTCCCTTCTTCTTCTTTTATCTCCAAGGTTAATC
 AGGAAAAATAGCTTTTGACAGGGGAAAAAATCAATAACTAGCTATTTTGGACCTCCTGA
 TCAGGAACCTTAGTTGAAGCGTAAATCTAAAGAAACATTTTCTCTGAAATATATTATTAA
 GGGCAATGGAGATAAATTAATAGTAGATGTGGTTCCTCAGAAAATATAATCAAAATTCAAA
 35 GATTTTTTTTTGTTTCTGTAACGGAACTAAATCAAATGATTACTAGTGTAAATAGTAGAT
 AACTTGTTTTTATTGTTGGTGCATATTAGTATAACTGTGGGTAGGTCGGGGAGAGGGTA
 AGGGAATAGATCACTCAGATGTATTTAGATAAGCTATTTAGCCTTTGATGGAATCATAA
 ATACAGTGAATACAATCCTTTGCATTGTTAAGGAGGTTTTTTGTTTTTAAATGGTGGGTC
 AAGGAGCTAGTTTACAGGCTTACTGTGATTTAAGCAAATGTGAAAAGTGAAACCTTAATT
 40 TTATCAAAAGAAATTTCTGTAAATGGTATGTCTCCTTAGAATACCCAAATCATAATTTTA
 TTTGTACACACTGTTAGGGGCTCATCTCATGTAGGCAGAGTATAAAGTATTACCTTTTGG
 AATTAAGGCCACTGACTGTTATAAAGTATAACAACACACATCAGGTTTTTAAAAAGCCTT
 GAATGGCCCTTGTCTTAAAAAGAAATTAGGAGCCAGGTGCGGTGGCACGTGCCGTGTAGTC
 CCAGCTCCTTGGGAGGCTGAGACAGGAGGATTCCTTGAGCCCTGGAGTTTGAGTCCAGCC
 45 TGGGTGACATAGCAAGACCCTGTCTTAAAAAGAAAAATGGGAAGAAAGACAAGGTAACATG
 AAGAAAGAAGAGATACCTAGTATGATGGAGCTGCAAATTTTCATGGCAGTTCATGCAGTCG
 GTCAAGAGGAGGATTTTGTGTTTGTAGTTTGCAGATGAGCATTCTAAAGCATTTTCCCTT
 GCTGTATTTTTTTGTATTATAAATTACATTGGACTTCATATATATAATTTTTTTTACAT
 TATATGTCTCTGTATGTTTTGAAACTCTTGTATTTATGATATAGCTTATATGATTTTTT
 50 TGCCTTGGTATACATTTTAAAAATATGAATTTAAAAAATTTTGTAAAAAATAAAATTCACA
 AAATTGTTTTGAAAAACAAAAA

ERMAP (erythroblast membrane-associated protein)

55 **(PSYCHMARKER 8; SEQ ID NO :8)**

ATGGAGATGG CGAGTTCTGC TGGCTCCTGG CTCTCTGGCT GCCTCATCCC TCTCGTCTTC
 CTCCGGCTGT CTGTGCATGT GTCAGGCCAC GCAGGGGATG CCGGCAAGTT CCACGTGGCC

CTACTAGGGG GCACAGCCGA GCTGCTCTGC CCTCTCTCCC TCTGGCCCGG GACGGTACCC
AAGGAGGTGA GGTGGCTGCG GTCCCCATTG CCGCAGCGTT CCCAGGCTGT TCACATATTG
CGGGATGGGA AGGACCAGGA TGAAGATCTG ATGCCGGAAT ATAAGGGGAG GACGGTGCTA
GTGAGAGATG CCCAAGAGGG AAGTGTCACT CTGCAGATCC TTGACGTGCG CCTTGAGGAC
5 CAAGGGTCTT ACCGATGTCT GATCCAAGTT GGAAATCTGA GTAAAGAGGA CACCGTGATC
CTGCAGGTTG CAGCCCCATC TGTGGGGAGT CTCTCCCCCT CAGCAGTGGC TCTGGCTGTG
ATCCTGCCTG TCCTGGTACT TCTCATCATG GTGTGCCTTT GCCTTATCTG GAAGCAAAGA
AGAGCAAAAG AAAAGCTTCT CTATGAACAT GTGACGGAGG TGGACAATCT TCTTTCAGAC
CATGCTAAAG AAAAAGGAAA ACTCCATAAA GCTGTCAAGA AACTCCGGAG TGAAGTGAAG
10 TTGAAAAGAG CTGCAGCAAA CTCAGGCTGG AGAAGAGCCC GGTTGCATTT TGTGGCAGTG
ACCCTGGACC CAGACACAGC ACATCCCAAA CTCATCCTTT CTGAGGACCA AAGATGTGTA
AGGCTTGGAG ACAGACGGCA GCCTGTACCT GACAACCCCC AGAGATTTGA TTTCGTTGTC
AGCATCCTAG GCTCTGAGTA CTTACGACT GGCTGCCACT ACTGGGAGGT GTATGTGGGA
GACAAGACCA AATGGATTCT TGGAGTATGT AGTGAGTCAG TGAGCAGGAA GGGGAAGGTT
15 ACTGCCTCAC CTGCCAATGG AACTTGGCTT CTGCGACAGA GTCGTGGGAA TGAGTATGAA
GCTCTCACAT CCCCAGAC CTCCTTCCGC CTTAAAGAGC CTCACGGTG TGTGGGGATT
TTCCTGGACT ATGAAGCAGG AGTCATCTCT TTCTACAATG TGACCAACAA GTCCACATC
TTTACTTTCA CCCACAATTT CTCTGGCCCC CTTGCGCCTT TCTTTGAACC TTGCCTTCAT
GATGGAGGAA AAAACACAGC ACCTCTAGTC ATTTGTTTCA AACTACACAA ATCAGAGGAA
20 TCAATTGTCC CCAGGCCAGA AGGGAAGGC CATGCTAATG GAGATGTGTC CCTCAAGGTG
AACTCTTCTT TACTACCCCC GAAGGCCCA GAGCTGAAGG ATATAATCCT GTCCTTGCCC
CCTGACCTTG GCCCAGCCCT TCAGGAGCTC AAGGCTCCTT CTTTTTAG

CGFLC 31120 (PSYCHMARKER 9 ; SEQ ID NO :9)

ACCGGTAATG ACCTCCGCGA TACCATACAC CATTGAGGTT GGAGTGGGCG CAGGCATGGT
ACCACCATCC CCCACGATGG TAGAGGGCAC AGTTGCCTGA GGGGGGAGAG AGAGGAGAGA
GAAAGAGACA GCATTCGATT TCCCCCAAA ATAAAAGGAT CTACCAGCAC TTTCTTTGGG
30 CAAAGCTT

LYPLA1 lysophospholipase 1 (PSYCHMARKER 10; SEQ ID NO :10)

AGCCGCTCGCACGCCCTTGGGCCGCGGCCGGGCGCCCGCTCTTCCCTTCCGCTTGCGCTGT
GAGCTGAGGCGGTGTATGTGCGGCAATAACATGTCAACCCCGCTGCCCGCCATCGTGCCC
GCCGCCCGGAAGGCCACCGCTGCGGTGATTTTCTTGCATGGATTGGGAGATACTGGGCAC
40 GGATGGGCAGAAGCCTTTGCAGGTATCAGAAGTTCACATATCAAATATATCTGCCCGCAT
GCGCCTGTTAGGCCCTGTTACATTAAATATGAACGTGGCTATGCCTTCATGGTTTGATATT
ATTGGGCTTTTACCAGATTACAGGAGGATGAATCTGGGATTAAACAGGCAGCAGAAAAT
ATAAAAGCTTTGATTGATCAAGAAGTGAAGAATGGCATTCTTCTAACAGAATTATTTTG
GGAGGGTTTTCTCAGGGAGGAGCTTTATCTTTATATACTGCCCTTACCACACAGCAGAAA
45 CTGGCAGGTGTCACATGCACAGTTGCTGGCTTCCACTTCGGGCTTCCCTTCCACAGGGT
CCTATCGGTGGTGCCTAATAGAGATATTTCTATTCTCCAGTGCCACGGGGATTGTGACCTT
TTGGTTCCCTTGATGTTTTGGTTCTCTTACGGTGGAAAACTAAAAACATTGGTGAATCCA
GCCAATGTGACCTTTAAAACCTATGAAGGTATGATGCACAGTTCTGTCTAACAGGAAATG
ATGGATGTCAAGCAATTCATTGATAAACTCCTACCTCCAATTGATTGACGTCACCTAAGAG
50 GCCTTGTGTAGAAGTACACCAGCATCATTGTAGTAGAGTGTAACCTTTTCCCATGCCCA
GTCTTCAAATTTCTAATGTTTTGCAGTGTTAAATGTTTTGCAAATACATGCCAATAACA
CAGATCAAATAATATCTCCTCATGAGAAATTTATGATCTTTTAAGTTTCTATACATGTAT
TCTTATAAGACGACCCAGGATCTACTATATTAGAATAGATGAAGCAGGTAGCTTCTTTTT
TCTCAAATGTAATTCAGCAAAATAACAGTACTGCCACCAGATTTTTTATTACATCATT
55 TGAAAATTAGCAGTATGCTTAATGAAAATTTGTTTCAAGGTATAAATGAGCAGTTAAGATAT
AAACAATTTATGCATGCTGTGACTTAGTCTATGGATTTATTCCAAAATGCTTAGTCACC
ATGCAGTGTCTGTATTTTTATATATGTGTTTATATATACATAATGATTATAATACATAAT
AAGAATGAGGTGGTATTACATTATCCCTAATAATAGGGATAATGCTGNTTATTGTCCAGG
AAAAAGTAAATCGGTCCCTTCAATTAAATGGCCCTTTTAAATNTNGGACCAGGCTTTTA

ATTTTCCCCGATATTAATTTCCAATTTAATACCCCTTTCCNCNCCAGAAAAAAAAAAAA
AGTTTGTTTTTTCCTTAATTGTCTTCATAGCAGGCCAAGTATTGCC

LDHA Lactate dehydrogenase A (PSYCHMARKER 11 ; SEQ ID NO :11)

5

ATGGCAACTC TAAAGGATCA GCTGATTTAT AATCTTCTAA AGGAAGAACA GACCCCCCAG
AATAAGATTA CAGTTGTTGG GGTTGGTGCT GTTGGCATGG CCTGTGCCAT CAGTATCTTA
ATGAAGGACT TGGCAGATGA ACTTGCTCTT GTTGATGTCA TCGAAGACAA ATTGAAGGGA
10 GAGATGATGG ATCTCCAACA TGGCAGCCTT TTCCTTAGAA CACCAAAGAT TGTCTCTGGC
AAAGACTATA ATGTAACGTC AAAC'TCCAAG CTGGTCATTA TCACGGCTGG GGCACGTCAG
CAAGAGGGAG AAAGCCGTCT TAATTTGGTC CAGCGTAACG TGAACATATT TAAATTCATC
ATTCCTAATG TTGTAAAATA CAGCCCGAAC TGCAAGTTGC TTATTGTTTC AAATCCAGTG
GATATCTTGA CCTACGTGGC TTGGAAGATA AGTGGTTTTT CCAAAAACCG TGTATTATGGA
15 AGTGGTTGCA ATCTGGATTG AGCCCGATTG CGTTACCTGA TGGGGGAAAG GCTGGGAGTT
CACCCATTAA GCTGTCATGG GTGGGTCCCTT GGGGAACATG GAGATTCCAG TGTGCCTGTA
TGGAGTGGAA TGAATGTTGC TGGTGTCTCT CTGAAGACTC TGCACCCAGA TTTAGGGACT
GATAAAGATA AGGAACAGTG GAAAGAGGTT CACAAGCAGG TGGTTGAGAG TGCTTATGAG
GTGATCAAAC TCAAAGGCTA CACATCCTGG GCTATTGGAC TCTCTGTAGC AGATTTGGCA
20 GAGAGTATAA TGAAGAATCT TAGGCGGGTG CACCCAGTTT CCACCATGAT TAAGGGTCTT
TACGGAATAA AGGATGATGT CTTCCTTAGT GTTCCTTGCA TTTTGGGACA GAATGGAATC
TCAGACCTTG TGAAGTGAC TCTGACTTCT GAGGAAGAGG CCCGTTTGAA GAAGAGTGCA
GATACACTTT GGGGATCCA AAAGGAGCTG CAATTTTAA

25

SCG3 (secretogranin III) (PSYCHMARKER 12 ; SEQ ID NO :12)

ATGGGGTTCC TCGGGACCGG CACTTGGATT CTGGTGTTAG TGCTCCCGAT TCAAGCTTTC
30 CCCAAACCTG GAGGAAGCCA AGACAAATCT CTACATAATA GAGAA'TTAAG TGCAGAAAGA
CCTTTGAATG AACAGATTGC TGAAGCAGAA GAAGACAAGA TTAaaaaaac ATATCCTCCA
GAAAACAAGC CAGGTCAGAG CAACTATTCT TTTGTTGATA ACTTGAACCT GCTAAAGGCA
ATAACAGAAA AGGAAAAAAT TGAGAAAGAA AGACAATCTA TAAGAAGCTC CCCACTTGAT
AATAAGTTGA ATGTGGAAGA TGTTGATTCA ACCAAGAATC GAAAACTGAT CGATGATTAT
35 GACTCTACTA AGAGTGGATT GGATCATAAA TTTCAAGATG ATCCAGATGG TCTTCATCAA
CTAGACGGGA CTCCTTTTAA CGCTGAAGAC ATTGTTCCATA AAATCGCTGC CAGGATTTAT
GAAGAAAATG ACAGAGCCGT GTTTGACAAG ATTGTTTCTA AACTACTTAA TCTCGGCCTT
ATCACAGAAA GCCAAGCACA TACACTGGAA GATGAAGTAG CAGAGGTTTT ACAAAAATTA
ATCTCAAAGG AAGCCAACAA TTATGAGGAG GATCCCAATA AGCCCAACAG CTGGACTGAG
40 AATCAGGCTG GAAAAATACC AGAGAAAGTG ACTCCAATGG CAGCAATTCA AGATGGTCTT
GCTAAGGGAG AAAACGATGA AACAGTATCT AACACATTAA CCTTGACAAA TGGCTTGGA
AGGAGAACTA AAACCTACAG TGAAGACAAC TTTGAGGAAC TCCAATATTT CCCAAATTC
TATGCGCTAC TGAAAAGTAT TGATTTCAGAA AAAGAAGCAA AAGAGAAAGA AACACTGATT
ACTATCATGA AAACACTGAT TGACTTTGTG AAGATGATGG TGAAATATGG AACAAATATCT
45 CCAGAAGAAG GTGTTTCCTA CCTTGAAAAC TTGGATGAAA TGATTGCTCT TCAGACCAAA
ACAAGCTAG AAAAAAATGC TACTGACAA'T ATAAGCAAGC TTTTCCCAGC ACCATCAGAG
AAGAGTCATG AAGAAACAGA CAGTACCAAG GAAGAAGCAG CTAAGATGGA AAAGGAATAT
GGAAGCTTGA AGGATTCCAC AAAAGATGAT AACTCCAACC CAGGAGGAAA GACAGATGAA
CCCAAAGGAA AAACAGAAAG CTATTTGGAA GCCATCAGAA AAAATATTGA ATGGTTGAAG
50 AAACATGACA AAAAGGGAAA TAAAGAAGAT TATGACCTTT CAAAGATGAG AGACTTCATC
AATAACAAG CTGATGCTTA TGTGGAGAAA GGCATCCTTG ACAAGGAAGA AGCCGAGGCC
ATCAAGCGCA TTTATAGCAG CCTGTAA

CG187232-01 (hypothetical protein)

(PSYCHMARKER 13 ; SEQ ID NO :13)

CAATAGAAATGTTTGGCTTTACCCATCAGCCAAATAAAAAAATCTCCTTGTAAGGTTAAA

AGGATCAAAATGTAGGAGACCGTGAATATTCACCAAAACCCTTCATCTTTTCAATTTCTT
CATCTGTTTTCTGGGCTGCTCATTTTGGATGCTTTATCTTGGTTACTACTACCAGTATTTG
CTTTAGATCGTTTTGTCTTGTGTATCTAACAACCGAGATCTCTTGAATTGCCATCTGTCAT
CTAAGTCTAAGGCCTTTATGCTTAATGATTTGTGGTGTACTAAC'TGGACTAGCTTCAGGAA
5 TGTCAGTGTGTTCTACCATTAAAGGTGAGATTGTCTACTACATCGAGATGGTGGTTGTAGT
TACAGCTACTTTTAGAAACATGTCTATTTTTTAAAGACATAACACATGAATGAAGAAATT
CAGAATTTGGAAAAAGGTCCGTAATGCC'TGACAAAGAAAAATGTTCTCCTGAGGGTCTT
TTTGGATGTTCTTCTCTCTTGC'TGCC'TGAATCTGTGCTCCTCTCCTTTTCTCAATTTCTC
10 GTTTTAATCTGTTTACATCCTTTACTAGTTTATCTACTGCTTGTTCAC'TGTCTTCCACTT
TTTTGCATATACTCCTTAATTCCTCTTGTAAATGAAGCATACATTTCA'TTTATCTTATGTA
CCTCCTTTAAGGATCCATCTTCTTCAAAAAATTTAGAGCTGTGTGTTTGTACTGCTCGGC
TAAAACCAGTGGACATACAGGAACCTGATACAGTTTTATAACCCAGTTGTTTCAGACATGC
CCAGATTGGCAACCCTAAAGGTACCC'TGTGAAAAAGTCC'TTTTGTAGGTTTATATAAGG
AATGTTCCAGTCGATGAGTAGAGCAGCTTCTGTTATTATAC'TTGGTGTTAATAGCAGAA
15 AAACAAGGTCTTGGTTTGA AAAATGCTCCTGCAAGTTTTTGTGAAGCAGCCTCTCTCTAA
ACGTCATGATCTGATCTGAATGACGACGGAATTTGTACCAACCTACCACATTC'TTTTTGA
CATTTGATAATATTTTCTTCAGTGC'TTGCTCATTTACTTCG

20

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages,
25 and modifications are within the scope of the following claims.